- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04.01. | Kyverna Therapeutics' IND application for MS therapy receives FDA clearance | ||
| 03.01. | WuXi XDC, IntoCell partner for drug-linker technology and CRDMO services | ||
| 02.01. | Alfasigma to acquire Galapagos' Jyseleca business | ||
| 29.12.23 | Palisade Bio receives milestone payment for PALI-2108 development | ||
| 28.12.23 | Eli Lilly concludes POINT Biopharma acquisition for $1.4bn | ||
| 27.12.23 | Innovent and SanegeneBio partner for hypertension drug development | ||
| 26.12.23 | FDA grants priority review for Daiichi Sankyo-Merck's lung cancer therapy | ||
| 22.12.23 | SELLAS receives orphan drug designation for PTCL therapy | ||
| 21.12.23 | Calliditas receives approval for Nefecon to treat IgAN | ||
| 20.12.23 | LimmaTech, AbVacc sign licensing agreement for S. aureus vaccine candidate | ||
| 19.12.23 | Allay grants acute pain management drug license to Japan's Maruishi Pharmaceutical | ||
| 18.12.23 | Arcutis Biotherapeutics receives FDA approval for ZORYVE to treat seborrheic dermatitis | ||
| 15.12.23 | Merck gets FDA approval for WELIREG to treat advanced renal cell carcinoma | ||
| 14.12.23 | Aldevron signs agreement to acquire license to Codex HiCap RNA Polymerase | ||
| 13.12.23 | Almirall signs alliance with etherna for new mRNA-based therapies | ||
| 12.12.23 | Lavipharm signs agreement with Sanofi to acquire Flagyl | ||
| 11.12.23 | Rigel, MD Anderson partner to expand REZLIDHIA assessment in AML | ||
| 08.12.23 | USFDA accepts NextPoint Therapeutics's IND for NPX887 | ||
| 07.12.23 | Voyager Therapeutics selects lead development candidate for SOD1 ALS gene therapy programme | ||
| 06.12.23 | Novartis receives FDA approval for Fabhalta to treat PNH in adults | ||
| 05.12.23 | China NMPA accepts Everest Medicines' IND application for zetomipzomib | ||
| 04.12.23 | AbbVie agrees to acquire ImmunoGen for around $10.1bn | ||
| 01.12.23 | Phenomic AI, Astellas partner to develop solid tumour cell therapies | ||
| 30.11.23 | US FDA accepts Karuna's NDA for schizophrenia therapy | ||
| 29.11.23 | Evommune, Accutar to discover drug candidates for chronic inflammatory diseases |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
